Contraception Adverse Effects

Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users

Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, Sorel M, Quesenberry CP, Cooper WO

Published January 2013 Contraception, 87(1), 93-100
DOI 10.1016/j.contraception.2012.09.015 PMID 23083525

Abstract

Background

Combined hormonal contraceptives (CHCs) place women at increased risk of venous thromboembolic events (VTEs) and arterial thrombotic events (ATEs), including acute myocardial infarction and ischemic stroke. There is concern that three recent CHC preparations [drospirenone-containing pills (DRSPs), the norelgestromin-containing transdermal patch (NGMN) and the etonogestrel vaginal ring (ETON)] may place women at even higher risk of thrombosis than other older low-dose CHCs with a known safety profile.

Study Design

All VTEs and all hospitalized ATEs were identified in women, ages 10-55 years, from two integrated health care programs and two state Medicaid programs during the time period covering their new use of DRSP, NGMN, ETON or one of four low-dose estrogen comparator CHCs. The relative risk of thrombotic and thromboembolic outcomes associated with the newer CHCs in relation to the comparators was assessed with Cox proportional hazards regression models adjusting for age, site and year of entry into the study.

Results

The hazards ratio for DRSP in relation to low-dose estrogen comparators among new users was 1.77 (95% confidence interval 1.33-2.35) for VTE and 2.01 (1.06-3.81) for ATE. The increased risk of DRSP was limited to the 10-34-year age group for VTE and the 35-55-year group for ATE. Use of the NGMN patch and ETON vaginal ring was not associated with increased risk of either thromboembolic or thrombotic outcomes.

Conclusions

In new users, DRSP was associated with higher risk of thrombotic events (VTE and ATE) relative to low-dose estrogen comparator CHCs, while the use of the NGMN patch and ETON vaginal ring was not.

Topics

By this author

Related research

Contraception › Adverse Effects › Venous Thromboembolism · Therapeutics › Prescribing Safety › Medication Safety in Pregnancy
Stephen Sidney, T Craig Cheetham, Frederick A Connell, Rita Ouellet-Hellstrom, David J Graham, Daniel Davis, Michael Sorel, Charles P Quesenberry, William O Cooper
Steve Sidney, S Sidney, Fred Connell, F Connell, R Ouellet-Hellstrom, Dave Graham, D Graham, Dan Davis, Danny Davis, D Davis, Mike Sorel, M Sorel, Charlie Quesenberry, Chuck Quesenberry, C Quesenberry, Bill Cooper, Will Cooper, Billy Cooper, W Cooper
PMID 23083525 23083525 DOI 10.1016/j.contraception.2012.09.015 10.1016/j.contraception.2012.09.015 Sidney et al. 2013, Sidney 2013